227 related articles for article (PubMed ID: 28701225)
1. Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.
Takiguchi K; Uezato A; Itasaka M; Atsuta H; Narushima K; Yamamoto N; Kurumaji A; Tomita M; Oshima K; Shoda K; Tamaru M; Nakataki M; Okazaki M; Ishiwata S; Ishiwata Y; Yasuhara M; Arima K; Ohmori T; Nishikawa T
BMC Psychiatry; 2017 Jul; 17(1):249. PubMed ID: 28701225
[TBL] [Abstract][Full Text] [Related]
2. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
3. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
4. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
Evins AE; Amico E; Posever TA; Toker R; Goff DC
Schizophr Res; 2002 Jul; 56(1-2):19-23. PubMed ID: 12084415
[TBL] [Abstract][Full Text] [Related]
5. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
[TBL] [Abstract][Full Text] [Related]
7. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
Goff DC; Herz L; Posever T; Shih V; Tsai G; Henderson DC; Freudenreich O; Evins AE; Yovel I; Zhang H; Schoenfeld D
Psychopharmacology (Berl); 2005 Apr; 179(1):144-50. PubMed ID: 15502972
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
9. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
Goff DC; Tsai G; Manoach DS; Coyle JT
Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.
Goff DC; Henderson DC; Evins AE; Amico E
Biol Psychiatry; 1999 Feb; 45(4):512-4. PubMed ID: 10071726
[TBL] [Abstract][Full Text] [Related]
11. Effects of D-cycloserine on negative symptoms in schizophrenia.
Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
[TBL] [Abstract][Full Text] [Related]
12. Extensive white matter abnormalities and clinical symptoms in drug-naive patients with first-episode schizophrenia: a voxel-based diffusion tensor imaging study.
Zhang XY; Fan FM; Chen DC; Tan YL; Tan SP; Hu K; Salas R; Kosten TR; Zunta-Soares G; Soares JC
J Clin Psychiatry; 2016 Feb; 77(2):205-11. PubMed ID: 26761708
[TBL] [Abstract][Full Text] [Related]
13. White Matter Abnormalities in Never-Treated Patients With Long-Term Schizophrenia.
Xiao Y; Sun H; Shi S; Jiang D; Tao B; Zhao Y; Zhang W; Gong Q; Sweeney JA; Lui S
Am J Psychiatry; 2018 Nov; 175(11):1129-1136. PubMed ID: 30068259
[TBL] [Abstract][Full Text] [Related]
14. The Paradoxical Relationship between White Matter, Psychopathology and Cognition in Schizophrenia: A Diffusion Tensor and Proton Spectroscopic Imaging Study.
Caprihan A; Jones T; Chen H; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C; Bustillo JR
Neuropsychopharmacology; 2015 Aug; 40(9):2248-57. PubMed ID: 25786581
[TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Heresco-Levy U; Ermilov M; Shimoni J; Shapira B; Silipo G; Javitt DC
Am J Psychiatry; 2002 Mar; 159(3):480-2. PubMed ID: 11870017
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Heresco-Levy U; Javitt DC
Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
[TBL] [Abstract][Full Text] [Related]
17. D-alanine added to antipsychotics for the treatment of schizophrenia.
Tsai GE; Yang P; Chang YC; Chong MY
Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
[TBL] [Abstract][Full Text] [Related]
18. D-cycloserine added to clozapine for patients with schizophrenia.
Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
[TBL] [Abstract][Full Text] [Related]
19. Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment.
Zeng B; Ardekani BA; Tang Y; Zhang T; Zhao S; Cui H; Fan X; Zhuo K; Li C; Xu Y; Goff DC; Wang J
Schizophr Res; 2016 Apr; 172(1-3):1-8. PubMed ID: 26852402
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Lane HY; Lin CH; Huang YJ; Liao CH; Chang YC; Tsai GE
Int J Neuropsychopharmacol; 2010 May; 13(4):451-60. PubMed ID: 19887019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
